Atkin S L, Masson E A, Blumhardt L D, White M C
Department of Endocrinology, Royal Liverpool Hospital, UK.
J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):371-2. doi: 10.1136/jnnp.57.3.371.
The cases are reported of two patients who developed benign intracranial hypertension after the withdrawal of the novel non-ergot derived dopamine agonist CV 205 502 (quinagolide).
报告了两例患者在停用新型非麦角衍生多巴胺激动剂CV 205 502(喹高利特)后发生良性颅内高压的病例。